caffeine has been researched along with Sleep Apnea Syndromes in 21 studies
Sleep Apnea Syndromes: Disorders characterized by multiple cessations of respirations during sleep that induce partial arousals and interfere with the maintenance of sleep. Sleep apnea syndromes are divided into central (see SLEEP APNEA, CENTRAL), obstructive (see SLEEP APNEA, OBSTRUCTIVE), and mixed central-obstructive types.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Potentially remediable risk factors include frequency of migraine attacks, obesity, excessive use of medications containing opioids and barbiturates, caffeine overuse, stressful life events, depression, sleep disorders and cutaneous allodynia." | 4.85 | What predicts the change from episodic to chronic migraine? ( Bigal, ME; Lipton, RB, 2009) |
| "Caffeine is the first-choice drug for the treatment for apnea of prematurity (AOP) in preterm infants and it has been reported that it improves the diaphragm activity." | 4.31 | Effects of caffeine on diaphragmatic activity in preterm infants. ( Ciarcià, M; Corsini, I; Dani, C; Fusco, M; Gitto, E; Leonardi, V; Manti, S; Marseglia, L, 2023) |
| "The treatment of neonatal apnea and bradycardia with methylated xanthines--theophylline and caffeine--is generally accepted." | 3.68 | [Effect of methylxanthines on periodic respiration and acid gastroesophageal reflux in newborn infants]. ( Heimann, G; Koch, G; Skopnik, H, 1990) |
| "An enzyme immunoassay technique (EMIT) for microdeterminations of caffeine was compared with high performance liquid chromatography (HPLC) and evaluated in 113 neonates and young infants, and in 18 asthmatic and 15 epileptic children." | 3.67 | Caffeine enzyme immunoassay in neonatal and pediatric drug monitoring. ( Aranda, JV; Beharry, K; Charest-Boule, L; Johannes, RJ; Rex, J, 1987) |
| "Caffeine treatment reduces the frequency of apnoea of prematurity (AOP) and eliminates the need for mechanical ventilation by acting as a nonspecific inhibitor of adenosine A1 and adenosine 2A receptors." | 2.77 | Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity. ( Duman, N; Kumral, A; Ozkan, H; Tuzun, F; Yesilirmak, DC, 2012) |
| "In a subgroup, migraine evolves into a more protracted condition (migraine transformation or progression)." | 2.45 | Migraine chronification--concept and risk factors. ( Bigal, M, 2009) |
| "Obstructive sleep apnea (OSA) was found on both polysomnograms but only on the PAT HSAT without alcohol, raising the possibility of two false negative PAT HSAT results after alcohol consumption." | 1.91 | Interaction between alcohol consumption and use of peripheral arterial tone home sleep apnea tests for sleep apnea evaluation. ( Devarajan, A; Krahn, LE; Lizak, M; Lyng, PJ; Paliwal, A; Ruoff, C, 2023) |
| "Caffeine is a routinely prescribed pharmacological active compound in neonatal intensive care units (NICU) for treating apnea of prematurity (AOP), which also decreases the risk of bronchopulmonary dysplasia and cerebral palsy in neonates." | 1.72 | Relationship of caffeine regimen with osteopenia of prematurity in preterm neonates: a cohort retrospective study. ( Ali, A; Ambreen, G; Hussain, K; Khan, M; Khan, MA; Khan, WA; Kumar, M; Naz, F; Salat, MS; Saleem, SM; Sohail, S, 2022) |
| "Caffeine use was quantified as the number of cans of soda or the cups of coffee or tea consumed daily." | 1.38 | Sleep-disordered breathing and caffeine consumption: results of a community-based study. ( Aurora, RN; Caffo, B; Crainiceanu, C; Punjabi, NM, 2012) |
| "Currently there is good evidence for treatment of obstructive sleep apnea (OSA) in CHF with continuous positive airway pressure; however, for central sleep apnea (CSA) the treatment is less clear." | 1.35 | Variation in severity and type of sleep-disordered breathing throughout 4 nights in patients with heart failure. ( Cowie, MR; Hastings, PC; Morrell, MJ; Papaioannou, I; Poole-Wilson, PA; Simonds, AK; Vazir, A, 2008) |
| "The pharmacokinetic profile of caffeine was studied in 15 premature infants." | 1.28 | Pharmacokinetic aspects of caffeine in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G, 1991) |
| "The caffeine half-life was 52." | 1.28 | Caffeine pharmacokinetics in preterm infants older than 2 weeks. ( Berlin, CM; Duran, C; Maisels, MJ; Pearlman, SA; Wood, MA, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (19.05) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, M | 1 |
| Ali, A | 1 |
| Khan, MA | 1 |
| Sohail, S | 1 |
| Saleem, SM | 1 |
| Khan, M | 1 |
| Naz, F | 1 |
| Khan, WA | 1 |
| Salat, MS | 1 |
| Hussain, K | 1 |
| Ambreen, G | 1 |
| Devarajan, A | 1 |
| Paliwal, A | 1 |
| Ruoff, C | 1 |
| Lyng, PJ | 1 |
| Lizak, M | 1 |
| Krahn, LE | 1 |
| Dani, C | 1 |
| Fusco, M | 1 |
| Manti, S | 1 |
| Marseglia, L | 1 |
| Ciarcià, M | 1 |
| Leonardi, V | 1 |
| Corsini, I | 1 |
| Gitto, E | 1 |
| Bigal, ME | 1 |
| Lipton, RB | 1 |
| Bigal, M | 1 |
| Funk, GD | 1 |
| Farahmand, N | 1 |
| Drennan, D | 1 |
| Junkins, S | 1 |
| Aurora, RN | 1 |
| Crainiceanu, C | 1 |
| Caffo, B | 1 |
| Punjabi, NM | 1 |
| Kumral, A | 1 |
| Tuzun, F | 1 |
| Yesilirmak, DC | 1 |
| Duman, N | 1 |
| Ozkan, H | 1 |
| Chardon, K | 1 |
| Bach, V | 1 |
| Telliez, F | 1 |
| Cardot, V | 1 |
| Tourneux, P | 1 |
| Leke, A | 1 |
| Libert, JP | 1 |
| Manni, R | 1 |
| Sances, G | 1 |
| Terzaghi, M | 1 |
| Ghiotto, N | 1 |
| Nappi, G | 1 |
| Vermeylen, D | 1 |
| Franco, P | 1 |
| Hennequin, Y | 1 |
| Pardou, A | 1 |
| Brugmans, M | 1 |
| Simon, P | 1 |
| Hassid, S | 1 |
| Vazir, A | 1 |
| Hastings, PC | 1 |
| Papaioannou, I | 1 |
| Poole-Wilson, PA | 1 |
| Cowie, MR | 1 |
| Morrell, MJ | 1 |
| Simonds, AK | 1 |
| Lee, TH | 1 |
| Curzi-Dascalova, L | 1 |
| Aujard, Y | 1 |
| Gaultier, C | 1 |
| Rajguru, M | 1 |
| De Carolis, MP | 1 |
| Romagnoli, C | 1 |
| Muzii, U | 1 |
| Tortorolo, G | 1 |
| Chiarotti, M | 1 |
| De Giovanni, N | 1 |
| Carnevale, A | 1 |
| Skopnik, H | 1 |
| Koch, G | 1 |
| Heimann, G | 1 |
| Pearlman, SA | 1 |
| Duran, C | 1 |
| Wood, MA | 1 |
| Maisels, MJ | 1 |
| Berlin, CM | 1 |
| Davis, JM | 1 |
| Zinman, R | 1 |
| Aranda, JV | 2 |
| Beharry, K | 1 |
| Rex, J | 1 |
| Johannes, RJ | 1 |
| Charest-Boule, L | 1 |
| Walsh, JK | 1 |
| Sugerman, JL | 1 |
| Chambers, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Sleep Heart Health Study (SHHS) Was a Multi-site Prospective Cohort Study to Investigate Obstructive Sleep Apnea (OSA) and Other Sleep-disordered Breathing (SDB) as Risk Factors for Cardiovascular Diseases and Hypertension[NCT00005275] | 6,441 participants (Actual) | Observational | 1994-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for caffeine and Sleep Apnea Syndromes
| Article | Year |
|---|---|
What predicts the change from episodic to chronic migraine?
Topics: Analgesics; Caffeine; Central Nervous System Stimulants; Chronic Disease; Clinical Trials as Topic; | 2009 |
Migraine chronification--concept and risk factors.
Topics: Caffeine; Disease Progression; Humans; Migraine Disorders; Obesity; Risk Factors; Sleep Apnea Syndro | 2009 |
Losing sleep over the caffeination of prematurity.
Topics: Animals; Caffeine; Humans; Infant, Newborn; Infant, Premature; Sleep; Sleep Apnea Syndromes; Sleep D | 2009 |
3 trials available for caffeine and Sleep Apnea Syndromes
| Article | Year |
|---|---|
Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity.
Topics: Bronchopulmonary Dysplasia; Caffeine; Case-Control Studies; Citrates; Drug Administration Schedule; | 2012 |
Hypnic headache: PSG evidence of both REM- and NREM-related attacks.
Topics: Age of Onset; Aged; Aged, 80 and over; Brain; Caffeine; Central Nervous System Stimulants; Cinnarizi | 2004 |
Laryngeal oedema in neonatal apnoea and bradycardia syndrome (a pilot study).
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Bradycardia; Caffeine; De | 2005 |
15 other studies available for caffeine and Sleep Apnea Syndromes
| Article | Year |
|---|---|
Relationship of caffeine regimen with osteopenia of prematurity in preterm neonates: a cohort retrospective study.
Topics: Bone Diseases, Metabolic; Caffeine; Cohort Studies; Female; Humans; Infant, Newborn; Infant, Prematu | 2022 |
Interaction between alcohol consumption and use of peripheral arterial tone home sleep apnea tests for sleep apnea evaluation.
Topics: Alcohol Drinking; Caffeine; Humans; Male; Middle Aged; Polysomnography; Sleep; Sleep Apnea Syndromes | 2023 |
Effects of caffeine on diaphragmatic activity in preterm infants.
Topics: Apnea; Caffeine; Diaphragm; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Sle | 2023 |
Patient education and self-advocacy: queries and responses on pain management.
Topics: Caffeine; Chronic Pain; Headache; Humans; Methadone; Pain Management; Sleep Apnea Syndromes | 2008 |
Sleep-disordered breathing and caffeine consumption: results of a community-based study.
Topics: Age Factors; Aged; Caffeine; Carbonated Beverages; Coffee; Data Collection; Drinking Behavior; Femal | 2012 |
Effect of caffeine on peripheral chemoreceptor activity in premature neonates: interaction with sleep stages.
Topics: Birth Weight; Body Temperature; Caffeine; Chemoreceptor Cells; Gestational Age; Humans; Infant; Infa | 2004 |
Variation in severity and type of sleep-disordered breathing throughout 4 nights in patients with heart failure.
Topics: Aged; Caffeine; Circadian Rhythm; Ethanol; Heart Failure; Humans; Male; Middle Aged; Monitoring, Amb | 2008 |
Puzzling through a case. The sleepless professor.
Topics: Age Factors; Aged; Anxiety; Caffeine; Central Nervous System Stimulants; Exercise; Humans; Male; Sle | 1999 |
Sleep organization is unaffected by caffeine in premature infants.
Topics: Caffeine; Cardiotocography; Citrates; Drug Combinations; Electrooculography; Humans; Infant, Newborn | 2002 |
Pharmacokinetic aspects of caffeine in premature infants.
Topics: Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature; Injections, Intravenous; Sl | 1991 |
[Effect of methylxanthines on periodic respiration and acid gastroesophageal reflux in newborn infants].
Topics: Bradycardia; Caffeine; Citrates; Drug Combinations; Drug Therapy, Combination; Gastric Acidity Deter | 1990 |
Caffeine pharmacokinetics in preterm infants older than 2 weeks.
Topics: Caffeine; Chromatography, High Pressure Liquid; Half-Life; Humans; Infant; Infant, Newborn; Infant, | 1989 |
Use of caffeine in the treatment of apnea associated with the Arnold-Chiari malformation.
Topics: Arnold-Chiari Malformation; Caffeine; Humans; Infant, Newborn; Male; Sleep Apnea Syndromes | 1989 |
Caffeine enzyme immunoassay in neonatal and pediatric drug monitoring.
Topics: Anticoagulants; Asthma; Caffeine; Chromatography, High Pressure Liquid; Humans; Immunoenzyme Techniq | 1987 |
Evaluation of insomnia.
Topics: Adolescent; Benzodiazepines; Caffeine; Chronic Disease; Ethanol; Humans; Muscle Contraction; Psychop | 1986 |